Innovative products are a central component of the CARB-X portfolio.
Find out more about our partners’ projects.
Breaching biofilms to prevent life-threatening infections
Full Story
CRISPR phages target E. coli with sharpshooter precision
Full Story
Using patterns to decode a sea of bacteria
Full Story
A portable, rapid diagnostic for remote settings
Full Story
The Brink examines the progress CARB-X has made as it addresses the health threat of antimicrobial resistance.
Full Story
How Entasis engineered ETX0462, a novel antibiotic that safely targets top biothreat pathogens
Full Story
Integrated BioTherapeutics’ toxin-targeted Staphylococcus aureus vaccine leverages a decade of hard-earned learnings
Full Story
Lumen's low-cost oral preventative binds and neutralizes Campylobacter jejuni and enterotoxigenic Escherichia coli (ETEC).
Full Story
Vedanta Biosciences’ new VE303 drug will prevent life-threatening C. difficile infections by boosting the body’s microbiome
Full Story
Cellics Therapeutics: Looking at drug development ‘upside down’
Full Story
Drug-resistant bacteria kill 700,000 people each year. The Boston Globe examines whether CARB-X can help solve the crisis.
Full Story
T2’s superbug detector is first product to launch from CARB-X
Full Story
If successful and approved for use in patients, Vaxcyte's (formerly SutroVax) new vaccine could prevent infections, and curb the spread of Group A Streptococcus (GAS) superbugs
Full Story
SciBac is fighting fire with fire by using improved bugs as drugs
Full Story
Vedanta is fighting superbugs by boosting the body's microbiome
Full Story
Bugworks is developing a ‘superdrug’ to treat superbugs
Full Story